Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study

What Was Tested

The paper reports a study of Somatostatin and Pasireotide, published as a randomized controlled trial.

In this analysis, the researchers evaluated the effect of pasireotide treatment on signs and symptoms in patients with Cushing's disease.

Who Took Part

According to the abstract, 3, patients were involved.

PubMed tags the participants as both men and women.

Changes in signs and symptoms of hypercortisolism over 12 months' treatment in patients still enroled in the study and with evaluable measurements were assessed in relation to degree of UFC control.

How the Study Was Run

The design is described as randomized, double-blind and open-label.

Random assignment meant chance, not the researchers, decided who got Somatostatin and who got the comparison, which limits bias.

Blinding on both sides kept the patients and researchers unaware of who received Somatostatin.

Being open-label, the Somatostatin study did not mask who received what.

The timeline in the abstract includes 12 months.

What Was Measured

PubMed files the paper under topics including Cholesterol, Cushing Syndrome, Lipoproteins, LDL, Somatostatin and Waist Circumference.

What This Means in Plain Language

The paper is a randomized, double-blind and open-label study of Somatostatin and Pasireotide in 3, patients over 12 months.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2014 (Clinical endocrinology), a journal based in England.

More context: the Somatostatin compound page and the Pasireotide compound page, all human trials.